SETD2 has been found to be mutated by 11.6%, respectively by 33.5% in ccRCC cohorts analysed by TCGA and by the Memorial-Sloan-Kettering Cancer Center [61]. Here, SETD2 is linked to nonpapillary renal cell carcinoma.